sparfloxacin has been researched along with isoniazid in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C | 1 |
Boukriche, Y; Fantin, B; Masson, C; Zarrouk, V | 1 |
1 review(s) available for sparfloxacin and isoniazid
Article | Year |
---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
9 other study(ies) available for sparfloxacin and isoniazid
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Isomerism; Isoniazid; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Splenomegaly; Survival Rate; Tuberculosis | 1995 |
[Efficacy of the sparfloxacin-ethambutol combination in a case of cerebral tuberculosis].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Rifampin; Tuberculosis, Central Nervous System | 2002 |